NEW YORK, Oct. 31, 2013 (GLOBE NEWSWIRE) -- Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, notes the announcement by Metabolon, Inc., a leader in metabolomics-based laboratory developed tests and research services, and Bostwick Laboratories, a full-service laboratory specializing in uropathology, particularly the diagnosis of urological cancers including prostate cancer, of the signing of an exclusive multi-year marketing agreement.
Under the agreement, Bostwick will market Prostarix, a non-invasive urine test for stratifying prostate cancer risk. The test will be offered for initial cancer evaluation to determine which men are candidates for prostate biopsy and also for repeat biopsy decision-making for men with prior negative biopsies. Sample testing for Prostarix will be performed in Metabolon's CLIA-certified, CAP-accredited laboratory utilizing its state-of-the-art mass spectroscopy-based analysis technology. The Agreement provides Metabolon with access to one of the largest urology networks in the United States.
"Metabolon continues to validate its metabolomics platform with the commercial launch of Prostarix and this marketing agreement with Bostwick," said Douglas Jamison, CEO of Harris & Harris Group. "You hear a great deal about genomic-based diagnostic tests, but these metabolomic-based tests are just as powerful, meet unmet needs, and are less expensive to perform, which leads to healthcare cost savings. We are excited to be a key investor in Metabolon, a leader in these metabolomic-based laboratory developed tests. Metabolon is one of the companies in our portfolio that best represents our thinking around our BIOLOGY+ investment thesis. The combination of biology with data is extremely powerful in predicting the development of disease." Metabolon's press release can be accessed at http://www.metabolon.com/news/PressReleases.aspx?year=2013&open=103013#103013_span.
This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2012, as well as subsequent filings, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business, including, but not limited to, the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties. The references to the websites www.HHVC.com, www.Facebook.com, and www.metabolon.com have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Harris & Harris Group is not responsible for the contents of third party websites.
CONTACT: DOUGLAS W. JAMISON TEL. NO. (212) 582-0900
|Harris & Harris Group Notes Metabolon's Collaboration Agreement With Human Longevity Inc. to Provide Metabolomic Profiling Services (2014/3/6)|
|Harris & Harris Group Notes Metabolon's Agreement With the Carlos Slim Institute, Patia and Clinica Ruiz for Quantose Prediabetes Test in Mexico (2014/2/25)|
|Harris & Harris Group Notes Metabolon's Closing on a $15 Million Series E Financing (2014/1/6)|
|Harris & Harris Group Notes Mersana's Collaboration Agreement With Subsidiary of Takeda Pharmaceutical Co. (2014/4/8)|
|Harris & Harris Group Notes D-Wave's Article in Phys.Org (2014/3/10)|
|Harris & Harris Group Notes the Closing of the Sale of Xradia to Carl Zeiss ()|
|Harris & Harris Group Notes D-Wave's Article in Time Magazine (2014/2/10)|
|Harris & Harris Group Notes Produced Water Absorbents to Acquire USA and Malaysia Assets of ProSep Inc. (2013/10/24)|
|Harris & Harris Group Notes ABSMaterials' Series B Financing ()|
|Harris & Harris Group Notes Molecular Imprints' Semiconductor Business to be Acquired by Canon (2014/2/14)|
|Harris & Harris Group, Inc.||View tiny Stock Quote|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.